Werewolf Therapeutics (NASDAQ:HOWL) Raised to “Hold” at Wall Street Zen

Werewolf Therapeutics (NASDAQ:HOWL) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Tuesday.

A number of other equities analysts have also weighed in on HOWL. Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, January 21st. Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research note on Friday, December 19th. Finally, HC Wainwright reduced their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.75.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $1.04 on Tuesday. The firm has a market capitalization of $50.54 million, a price-to-earnings ratio of -0.76 and a beta of 0.54. The business has a fifty day moving average of $0.73 and a 200 day moving average of $1.00. Werewolf Therapeutics has a 1 year low of $0.53 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Friday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.14. As a group, equities research analysts expect that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Insider Transactions at Werewolf Therapeutics

In related news, Director Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $0.57, for a total value of $33,618.60. Following the sale, the director directly owned 2,309,869 shares in the company, valued at approximately $1,316,625.33. The trade was a 2.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 253,298 shares of company stock valued at $143,888. Insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $409,000. Finally, Citadel Advisors LLC acquired a new position in shares of Werewolf Therapeutics during the 3rd quarter worth approximately $304,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.